Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Smartphone EEG Utility and Quality for Epilepsy Patients in the West African Republic of Guinea
Global Health and Neuroepidemiology
P9 - Poster Session 9 (12:00 PM-1:00 PM)
13-007
To assess the applicability of a smartphone-based electroencephalography (EEG), the Smartphone Brain Scanner-2 in a low-income country, including quality of results and usefulness of repeat testing.
People with epilepsy in Sub-Saharan Africa are often undiagnosed. We examine a low-cost, portable smartphone-based EEG technology in a heterogeneous epilepsy cohort in the West African Republic of Guinea.

The SBS2 system consists of an Android tablet wirelessly connected to a 14-electrode EasyCap headset. SBS2 was performed in people with suspected epilepsy in Guinea (2018-19), with a repeat EEG carried out at a variable time interval. Recordings were interpreted by U.S., Canadian, and U.K. experts in Clinical Neurophysiology.

We included 149 participants (41% female, median age 17.9 years). 66.6% ≤ 21 years; mean number of seizures per month 5.7 +/-15.5. The mean duration of EEG1 was 53 minutes +/-12.3 and EEG2 was 29.6 minutes +/-12.8. The mean quality score of EEG1 and EEG2 independently was 6.4 (range 1(low)-10(high), median 7.0). 29.5% of participants had epileptiform discharges (EDs) at EEG1 and 16.7% at EEG2. 41.6% had abnormal slowing and/or EDs at EEG1 and 28.8% at EEG2. 26.1% were recommended for neuro-imaging after EEG1 and 14.7% after EEG2. Of those without EDs at EEG1 (n=53, 55.8%), 7 (13.2%) had EDs at EEG2. Of those with detectable EDs on EEG1 (n = 23, 24.2%), 12 (52.1%) did not have EDs at EEG2. Patients for whom at least one EEG was not scored for EDs were excluded from the comparative ED analysis (n = 54, 36%).
The SBS2 has a reproducible level of quality on repeat testing and is useful for the detection of EDs. One EEG of approximately 50 minutes was adequate to support diagnosis. The need for neuroimaging access in this patient population is evident.
Authors/Disclosures
Farrah J. Mateen, MD, PhD, FÂ鶹´«Ã½Ó³»­ (Northwestern University Department of Neurology)
PRESENTER 		Dr. Mateen has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Mateen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Mateen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Mateen has received research support from Genentech. The institution of Dr. Mateen has received research support from Amgen. The institution of Dr. Mateen has received research support from TG Therapeutics. Dr. Mateen has received intellectual property interests from a discovery or technology relating to health care.
No disclosure on file
No disclosure on file
No disclosure on file
Jennifer Williams, MD (Massachusetts General Hospital, Brigham, Harvard) No disclosure on file
Andre Vogel (Massachusetts General Hospital) No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Vidita Khatri, MD No disclosure on file
Gladia C. Hotan (Department of Brain and Cognitive Sciences, MIT) Ms. Hotan has received research support from Institute of High Performance Computing.
Neishay Ayub, MD (Brown Neurology) The institution of Dr. Ayub has received research support from Brown Physicians Incorporated. The institution of Dr. Ayub has received research support from Pappitto Opportunity Connection.
Edward C. Leung, MD (Health Sciences Centre) No disclosure on file
Tadeu Fantaneanu, MD Dr. Fantaneanu has nothing to disclose.
Archana A. Patel, MD, MPH, MSc Dr. Patel has received research support from NIH/NINDS.
Manav Vyas, MD (MV VYAS MEDICINE PROFESSIONAL CORPORATION) The institution of Dr. Vyas has received research support from Heart and Stroke Foundation of Canada . The institution of Dr. Vyas has received research support from Canadian Institutes of Health Research . Dr. Vyas has received research support from Heart and Stroke Foundation of Canada .
Tracey A. Milligan, MD, FÂ鶹´«Ã½Ó³»­ Dr. Milligan has received publishing royalties from a publication relating to health care.
Mauricio F. Villamar, MD, FÂ鶹´«Ã½Ó³»­ (Department of Neurology, The Warren Alpert Medical School of Brown University) Dr. Villamar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Villamar has or had stock in Ceribell.Dr. Villamar has received research support from Brown Physicians Inc.. Dr. Villamar has a non-compensated relationship as a Member of Editorial Board with Neurology: Clinical Practice that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Villamar has a non-compensated relationship as a Member of Editorial Board with The Neurohospitalist that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Villamar has a non-compensated relationship as a Co-Chair - Quality Improvement Committee with American Clinical Neurophysiology Society that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Villamar has a non-compensated relationship as a Co-Leader, Practice and Compensation Survey Working Group with The Neurohospitalist Society that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Daniel Hoch, MD, PhD, FÂ鶹´«Ã½Ó³»­ (Massachusetts General Hospital) No disclosure on file
Sherrill J. Purves, MD, FÂ鶹´«Ã½Ó³»­ (Title) No disclosure on file
Behnaz Esmaeili, MD (University of Washington) No disclosure on file
No disclosure on file
Ernesto Gonzalez-Giraldo, MD (University of California, San Francisco) Dr. Gonzalez-Giraldo has nothing to disclose.
Illya Tolokh, MD (Massachusetts General Hospital, Brigham, Harvard) Dr. Tolokh has nothing to disclose.
Lauren L. Heidarian, MD (Intermountain Healthcare) No disclosure on file
Lila T. Worden, MD (Connecticut Children's Neurology) No disclosure on file
Neville Jadeja, MD, MPH (UMass Chan Medical School) No disclosure on file
Sara Molisani, MD (Children's Hospital Of Philadelphia) Dr. Fridinger has nothing to disclose.
Liesly Lee, MD (Sunnybrook Health Sciences Centre) Dr. Lee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Lee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Lee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi-Aventis. Dr. Lee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Lee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Lee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Lee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Lee has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis.
No disclosure on file